Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study

Marina Chiara Garassino, Byoung Chul Cho, Joo-Hang Kim, +148

The Lancet Oncology

MedicineImmunologyPathologyImmune Checkpoint InhibitorCancer Treatment +3

Prevention, Diagnosis, Therapy, and Follow-up of Lung Cancer

G. Goeckenjan, H. Sitter, Michael Thomas, +81

Pneumologie

Advanced Lung DiseaseInterdisciplinary GuidelineClinical SpecialtiesClinical GuidelinesOncology +23

Association of microsomal epoxide hydrolase polymorphisms and lung cancer risk

Andrea Gsur, Thomas Zidek, K Schnattinger, +10

British Journal of Cancer

Cervical Ultrasound (US) and US-guided Lymph Node Biopsy as a Routine Procedure for Staging of Lung Cancer

Helmut Prosch, Gerhard F. Strasser, C Sonka, +4

Ultraschall in der Medizin - European Journal of Ultrasound

Medical UltrasoundEngineeringPathologyThoracic UltrasoundOncology +16

Vinorelbine—gemcitabine in advanced non-small-cell lung cancer (NSCLC): An AASLC phase II trial

G. Krajnik, Andrea Mohn-Staudner, J. Thaler, +10

Annals of Oncology

OncologyMedicinePharmacotherapyAnti-cancer AgentCancer Treatment +3

Genetic polymorphisms of CYP1A1 and GSTM1 and lung cancer risk.

Andrea Gsur, Gerald Haidinger, Peter Hollaus, +8

PubMed

Cancer RiskCancer EpidemiologyOncogenic AgentMedicineGenetics +12

Vinorelbine/gemcitabine in advanced non-small cell lung cancer (NSCLC): a phase I trial

G. Krajnik, Wolfgang Wein, Richard Greil, +7

European Journal of Cancer

OncologyMedicinePharmacotherapyAnti-cancer AgentCancer Treatment +3

Docetaxel in the treatment of non-small cell lung cancer (NSCLC) -- an observational study focusing on symptom improvement.

Andreas Pircher, Ines Wasle, Michael Mian, +6

PubMed

Multicenter phase II study evaluating docetaxel and cisplatin as neoadjuvant induction regimen prior to surgery or radiochemotherapy with docetaxel, followed by adjuvant docetaxel therapy in chemonaive patients with NSCLC stage II, IIIA and IIIB (TAX-AT 1.203 Trial)

Florian Kocher, Andreas Pircher, Andrea Mohn-Staudner, +8

Lung Cancer

Tax-at 1.203Surgical OncologyOncologyMetronomic TherapyClinical Trials +10

Advanced non-small-cell lung cancer: adjunctive interferon γ in induction and maintenance therapy

C. Prior, S. Oroszy, W. Oberaigner, +5

Journal of Cancer Research and Clinical Oncology

MedicineImmunologyMaintenance TherapyBronchial NeoplasmCancer Treatment +5